Remarkable progress is being made in the implementation of novel cell-based
immunotherapeutics in solid organ transplantation studies. It is hoped that these new …

Although transplantation tolerance is still on its way to be reliably accomplished in clinical
settings, use of well specified and functionally characterized cellular therapeutics with …

Transplantation is the only cure for end-stage organ failure. Current immunosuppressive
drugs have two major limitations: 1) non antigen specificity, which increases the risk of …

Purpose To give an overview over cell therapeutic approaches to immunosuppression in
clinical kidney transplantation. A focus is on myeloid suppressor cell therapy by mitomycin C …

The effective development of innovative surgical applications and immunosuppressive
agents have improved remarkable advancements in solid organ transplantation. Despite …

Solid organ transplantation provides lifesaving therapy for patients with end stage organ
disease. In order for the transplanted organ to survive, the recipient must take a lifelong …

Organ transplantation has evolved into a reliable lifesaving procedure where good organ
function is quickly restored by the transplant and, typically, the patient can return to an active …

Despite preservation methods, surgical procedures, current immunosuppressive therapy
regimens advances, organ transplantation is accompanied with a poor long-term survival …

Solid organ transplantation is the treatment of choice for patients with end-stage organ
dysfunction. Despite improvements in short-term outcome, long-term outcome is suboptimal …

Abstract immunosuppression therapy is the key to successful post-transplantation outcomes.
The need for ideal immunosuppression became durable maintenance of long-term graft …